Detalhe da pesquisa
1.
Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.
Am J Hematol
; 91(12): 1206-1214, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27531525
2.
Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib.
Am J Hematol
; 91(6): 606-16, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26971533
3.
Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.
Cancer
; 121(9): 1405-13, 2015 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25641662
4.
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
Am J Hematol
; 90(9): 755-68, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26040495
5.
Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma.
Cancer
; 120(12): 1871-80, 2014 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24634003
6.
Heterogeneity of Patients With Intermediate-Prognosis Metastatic Renal Cell Carcinoma Treated With Sunitinib.
Clin Genitourin Cancer
; 15(2): 291-299.e1, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27638198
7.
Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Practical Clinical Implications of Pharmacologic Features.
Clin Genitourin Cancer
; 15(1): 7-22, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27473523
8.
Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias.
Clin Lymphoma Myeloma Leuk
; 17(10): 684-695.e6, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28807791
9.
The effect of information on preferences for treatments of metastatic renal cell carcinoma.
Curr Med Res Opin
; 32(11): 1827-1838, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27404275
10.
Response to Miller et al: resistant mutations in CML and Ph(+) ALL - role of ponatinib.
Biologics
; 9: 23-4, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25733805
11.
Clinical trials referral resource. Current clinical trials of molecularly targeted agents in children with cancer, Part 2.
Oncology (Williston Park)
; 16(4): 474, 479-80, 483-4 passim, 2002 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-12017535